Skip to main content
Ichiro Nakano, MD, Neurosurgery, Birmingham, AL

IchiroNakanoMDPhD

Neurosurgery Birmingham, AL

Brain & Spinal Tumor

Professor/Neurosurgery

Dr. Nakano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Nakano's full profile

Already have an account?

  • Office

    The Kirklin Clinic of UAB Hospital
    2000 6th Avenue South
    Birmingham, AL 35233
    Phone+1 205-934-7170
    Fax+1 205-934-6507
  • Is this information wrong?

Summary

  • I am a fellowship-trained neuro-oncology surgeon, specialized in the surgical care of brain tumors. I lead the Neuro-Oncology Program in the Comprehensive Cancer Center at UAB as co-Leader. I also contribute to various clinical trials for brain tumors.

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Neurosurgical Oncology, 2009 - 2012
  • Ronald Reagan UCLA Medical Center
    Ronald Reagan UCLA Medical CenterPost-Doctoral Fellowship, General Neurosurgery, 2006 - 2009
  • Faculty of Medicine Kyoto University
    Faculty of Medicine Kyoto UniversityClass of 1993

Certifications & Licensure

  • CA State Medical License
    CA State Medical License Current
  • OH State Medical License
    OH State Medical License 2012 - 2026
  • AL State Medical License
    AL State Medical License 2015 - 2020

Awards, Honors, & Recognition

  • Young Investigator Award American Association of Neurological Surgeons, 2006-2007

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Article Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma via Intercellular Transfer of Splicing Factors  
    Ahmed Mohyeldin, Ichiro Nakano, L James Lee, ScienceDirect
  • Combined c-met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma  
    Ichiro Nakano, Benjamin Purow, Clinical Cancer Research

Authored Content

  • On-Chip Clonal Analysis of Glioma-Stem-Cell Motility and Therapy ResistanceJuly 2016

Press Mentions

  • Sustained NF-κB-STAT3 Signaling Promotes Resistance to Smac Mimetics in Glioma Stem-like Cells but Creates a Vulnerability to EZH2 Inhibition
    Sustained NF-κB-STAT3 Signaling Promotes Resistance to Smac Mimetics in Glioma Stem-like Cells but Creates a Vulnerability to EZH2 InhibitionMarch 4th, 2019
  • Dying Cancer Cells Make Remaining Glioblastoma Cells More Aggressive and Therapy-Resistant
    Dying Cancer Cells Make Remaining Glioblastoma Cells More Aggressive and Therapy-ResistantJune 22nd, 2018
  • Dying Cancer Cells Make Remaining Glioblastoma Cells More Aggressive and Therapy-Resistant
    Dying Cancer Cells Make Remaining Glioblastoma Cells More Aggressive and Therapy-ResistantJune 21st, 2018
  • Join now to see all

Grant Support

  • National Institute for HealthNational Cancer InstitutePresent

Research History

  • ProfessorTherapy development and clinical trials for malignant brain tumors2015 - Present
  • Associate ProfessorTherapy development and clinical trials for brain tumors2009 - 2015

Professional Memberships

Other Languages

  • Japanese